<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418922</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-J081-117</org_study_id>
    <nct_id>NCT03418922</nct_id>
  </id_info>
  <brief_title>A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma</brief_title>
  <official_title>A Phase 1b Trial of Lenvatinib Plus Nivolumab in Subjects With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the tolerability and safety of a
      combination of lenvatinib plus nivolumab in participants with hepatocellular carcinoma (HCC).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Number of Participants with Any Serious and/or Non-serious Adverse Event</measure>
    <time_frame>From the date of screening until 30 days after the last dose (up to 41 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Overall Response Rate (ORR)</measure>
    <time_frame>From the date of screening until the last observation visit (up to 41 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Plasma Concentrations of Lenvatinib</measure>
    <time_frame>Part 1, Cycle 1 Days 1 and 15: Pre-dose-24 hours, thereafter every Cycle Day 1 (Up to Cycle 24): Pre-dose; Part 2, Cycle 1 Day 1: 0.5-4 hours, Cycle 1 Day 15: Pre-dose-4 hours, Cycle 2, 4, 6 Day 1: Pre-dose (Cycle length is equal to [=] 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Serum Concentration of Nivolumab</measure>
    <time_frame>Part 1 and Part 2, Cycle 1 and 5 Day 1: Pre-dose and Just before completion of administration, Cycles 1 and 5 Day 15, Cycle 2, 3, 4, 9, 13 Day 1: Pre-dose, thereafter every 4 cycles Day 1: Pre-dose (Cycle length=28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Part 1: Lenvatinib Plus Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive specified doses of lenvatinib (oral) and nivolumab (intravenous) on specified days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Lenvatinib Plus Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If tolerable in Part 1, participants will receive specified doses of lenvatinib and nivolumab on specified days until criteria for discontinuation are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Specified doses will be administered orally on specified days.</description>
    <arm_group_label>Part 1: Lenvatinib Plus Nivolumab</arm_group_label>
    <arm_group_label>Part 2: Lenvatinib Plus Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified doses will be administered intravenously on specified days.</description>
    <arm_group_label>Part 1: Lenvatinib Plus Nivolumab</arm_group_label>
    <arm_group_label>Part 2: Lenvatinib Plus Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have confirmed diagnosis of hepatocellular carcinoma (HCC) with any
             of the following criteria:

               -  Histologically or cytologically confirmed diagnosis of HCC, excluding
                  fibrolamellar, sarcomatoid or mixed cholangio-HCC tumors

               -  Clinically confirmed diagnosis of HCC according to American Association for the
                  Study of Liver Diseases criteria, including cirrhosis of any etiology and/or
                  chronic hepatitis B or C infection

          -  Part 1: HCC for which no other appropriate therapy is available; Part 2: No prior
             systemic therapy for advanced/unresectable HCC

          -  Participants categorized to stage B (not applicable for transarterial
             chemoembolization), or stage C based on Barcelona Clinic Liver Cancer staging system

          -  Child-Pugh score A

          -  Participants must have an Eastern Cooperative Oncology Group Performance Status of 0
             to 1

          -  Age â‰¥20 years at the time of informed consent

        Exclusion Criteria:

          -  Active co-infection with hepatitis B and hepatitis C

          -  Participants with any active, known, or suspected autoimmune disease

          -  Participants being treated with drugs that strongly inhibit or induce CYP3A4 and that
             may be possibly used during this study

          -  Females who are breastfeeding or pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eisai Trial Site 1</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 6</name>
      <address>
        <city>Iizuka</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 3</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 4</name>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 2</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site 5</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

